The Impact of Prenatal Organophosphate Pesticide Exposures on Thai Infant Neurodevelopment

Pornpimol Kongtip1, Benyachalee Techasaensiri2, Noppanun Nankongnab3

  • 1Department of Occupational Health and Safety, Faculty of Public Health, Mahidol University, 420/1 Rajvithi Road, Bangkok 10400, Thailand. pornpimol.kon@mahidol.ac.th.

Insights

Prenatal exposure to organophosphate pesticides, measured by maternal urinary metabolites like DEP and DAP, was linked to lower infant motor and cognitive scores. Public health interventions are needed to reduce pesticide exposure during pregnancy.

Area of Science:

  • Environmental Health
  • Neurodevelopmental Pediatrics
  • Toxicology

Background:

  • Pesticide exposure during pregnancy is a growing concern.
  • Understanding the impact of prenatal pesticide exposure on infant neurodevelopment is crucial.

Purpose of the Study:

  • To investigate organophosphate pesticide exposure levels in pregnant Thai women.
  • To examine the association between prenatal pesticide exposure and infant neurodevelopment at five months.

Main Methods:

  • Birth cohort study in Thailand.
  • Maternal urinary metabolite analysis (organophosphates: DMP, DEP, DAP) via gas chromatography-mass spectrometry at 28 weeks gestation.
  • Infant neurodevelopmental assessment using Bayley Scales of Infant and Toddler Development-III at five months.

Main Results:

  • Higher maternal urinary total DEP and DAP levels were significantly associated with reduced infant motor composite scores.
  • Higher total DEP levels were also significantly associated with reduced infant cognitive composite scores.
  • Prenatal pesticide metabolite concentrations correlated with infant cognitive and motor development outcomes.

Conclusions:

  • Prenatal organophosphate pesticide exposure is linked to adverse infant neurodevelopmental outcomes.
  • Results highlight the need for public health interventions to mitigate pesticide exposure in pregnant women.
  • Reducing agricultural and domestic pesticide use is recommended to protect fetal development.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.9K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293